JW Pharmaceutical Corp Asset Resilience Ratio
JW Pharmaceutical Corp asset resilience ratio. JW Pharmaceutical Corp (001067) has an Asset Resilience Ratio of 8.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of JW Pharmaceutical Corp to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of JW Pharmaceutical Corp (2014–2024)
Asset resilience ratio of JW Pharmaceutical Corp from 2014 to 2024. This chart shows how JW Pharmaceutical Corp's Asset Resilience Ratio has changed over time. Read how much debt does JW Pharmaceutical Corp carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down JW Pharmaceutical Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 001067 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩49.95 Billion | 8.17% |
| Total Liquid Assets | ₩49.95 Billion | 8.17% |
Asset Resilience Insights
- Limited Liquidity: JW Pharmaceutical Corp maintains only 8.17% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
JW Pharmaceutical Corp Industry Peers by Asset Resilience Ratio
Compare JW Pharmaceutical Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
JW Pharmaceutical Corp Asset Resilience Ratio by Year (2014–2024)
JW Pharmaceutical Corp asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for JW Pharmaceutical Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.66% | ₩22.12 Billion ≈ $14.99 Million |
₩604.60 Billion ≈ $409.73 Million |
-8.48pp |
| 2023-12-31 | 12.14% | ₩78.29 Billion ≈ $53.05 Million |
₩645.04 Billion ≈ $437.13 Million |
-6.30pp |
| 2022-12-31 | 18.44% | ₩115.78 Billion ≈ $78.46 Million |
₩627.97 Billion ≈ $425.57 Million |
+13.34pp |
| 2021-12-31 | 5.10% | ₩32.30 Billion ≈ $21.89 Million |
₩633.05 Billion ≈ $429.01 Million |
-3.06pp |
| 2020-12-31 | 8.17% | ₩44.84 Billion ≈ $30.39 Million |
₩549.09 Billion ≈ $372.11 Million |
+8.16pp |
| 2016-12-31 | 0.00% | ₩20.00 Million ≈ $13.55K |
₩651.08 Billion ≈ $441.23 Million |
0.00pp |
| 2015-12-31 | 0.00% | ₩30.00 Million ≈ $20.33K |
₩613.48 Billion ≈ $415.75 Million |
0.00pp |
| 2014-12-31 | 0.01% | ₩30.00 Million ≈ $20.33K |
₩589.24 Billion ≈ $399.32 Million |
-- |
About JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more